NEWARK, N.J. AP – Attorneys for a Minnesota family suing to gain access to an experimental muscular dystrophy drug for their 16-year-old son argued on Tuesday that a drug company led them to believe they could participate in a clinical trial but then went back on their word.
Jacob Gunvalson and his parents want PTC Therapeutics of South Plainfield to provide him with the drug, PTC124. Jacob suffers from Duchenne muscular dystrophy, a rare and deadly condition that mainly strikes young boys and causes steady deterioration of muscle tissue.
